Halozyme Therapeutics: Innovating Drug Delivery with ENHANZE® and Hypercon™ Technologies

Halozyme Therapeutics: Pioneering Advanced Drug Delivery Solutions

Halozyme Therapeutics, Inc., a biopharmaceutical leader based in San Diego, is poised to showcase its innovative approaches to drug delivery at the upcoming 8th Annual Evercore Healthcare Conference on December 2, 2025. President and CEO Dr. Helen Torley will present the company's cutting-edge advancements, including its proprietary ENHANZE® technology, which has positively impacted the lives of over one million patients globally. This platform utilizes the enzyme rHuPH20 to enhance the delivery of biologics, making treatments more effective and accessible. The company's success is underscored by its partnerships with leading pharmaceutical giants such as Roche, Takeda, Pfizer, and AbbVie, facilitating the commercialization of ten products across more than 100 markets.

Halozyme's commitment to innovation continues with the development of its Hypercon™ technology, which introduces a novel microparticle system designed to optimize drug delivery. By allowing for hyper-concentration, this technology aims to reduce injection volumes, thus enhancing the feasibility of at-home administration for patients. Noteworthy collaborations with major players like Johnson & Johnson and Eli Lilly highlight the industry’s recognition of Halozyme’s potential to transform patient care through improved delivery systems. The focus on reducing the burden of traditional administration methods aligns with the growing demand for convenience in healthcare solutions.

Moreover, Halozyme is advancing its portfolio of drug-device combination products that leverage sophisticated auto-injector technologies. These initiatives aim to elevate patient experiences by providing easier and more efficient methods of receiving therapies. With proprietary products such as Hylenex® and XYOSTED®, as well as collaborations with organizations like Teva Pharmaceuticals, Halozyme is strategically positioned to enhance treatment adherence and outcomes across various patient demographics. The company's comprehensive approach to drug delivery not only addresses current healthcare challenges but also anticipates future needs within the evolving landscape.

In addition to its technological advancements, Halozyme maintains a strong presence in the biopharmaceutical community with offices in New Jersey, Minnesota, and Massachusetts. The company emphasizes its dedication to improving patient outcomes and experiences, reinforcing its commitment to innovation in drug delivery. For those interested in learning more about Halozyme’s initiatives, the company invites engagement on its Investor Relations website and social media platforms.

Halozyme Therapeutics stands at the forefront of biopharmaceutical innovation, continually striving to enhance drug delivery methods and patient experiences through its advanced technologies and strategic partnerships.